1. Pharma industry pushing back on Trump's 'Buy American' order — Pharma showering Congress with campaign donations — Kodak's $765M drug manufacturing loan on the rocks — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Eh?

Discussion in 'Aerie Pharma' started by anonymous, Mar 13, 2019 at 10:00 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Great idea by whomever it was to release “net cash burn guidance” 10min after rocklatan approval announcement.

    NOT!
     

  2. anonymous

    anonymous Guest

    No roclatan excitement????
     
  3. anonymous

    anonymous Guest

    Why would there be?.."The Rock" is marginally better than Latanoprost, yet it's about 50 times more expensive, and 100 times more difficult to RX..
     
  4. anonymous

    anonymous Guest

    According to the study (Mercury 1, phase 3), 82% of Roclatan patients achieved an IOP of 18 mm Hg or less compared with 57% of patients who received netarsudil and 68% of patients who received latanoprost...So, Roclatan only had about a 14% better rate of effectiveness vs generic Latanoprost, and it's how much more expensive?...Yeah, no wonder docs aren't impressed..
     
  5. anonymous

    anonymous Guest

    If you are a favored employee here you can use specialty pharmacies and other company resources to get ROCK approved for patients

    Ask your manager about this.
     
  6. anonymous

    anonymous Guest

    Lie, cheat and steal!!!!!
     
  7. anonymous

    anonymous Guest

    WRONG!! Roc demonstrates a 20% improvement over latan iop base! Plus Roc AE profile is superior to latan! Docs are IMPRESSED! If you sell without enthusiasm, you willl not be successful!!
     
  8. anonymous

    anonymous Guest

    Dude, during the Mercury 2 trials, Roc only reduced IOP between 1.5 mm Hg and 2.4 mm Hg more than latanoprost alone...Docs ARE NOT excited about this because any doc will tell you it would take years -if not a decade- for that extra 2 mm to make any difference, and they damn sure aren't going to jump through a bunch of manged care hoops to RX it...If you are walking into your offices all giddy, and excited over these studies, your docs think you're a brain dead moron..
     
  9. anonymous

    anonymous Guest

    Pfft, listen Aerie-hater troll. You know nothin about nothin.

    It’ll sell and you can keep lecturing everyone on what docs are gonna do cause you can read their minds,

    Now go sell your dinosaur drops before they fall off the patent cliff.
     
  10. anonymous

    anonymous Guest

    I don't sell drops, bro, and I know pretty much everything about Aerie, and their irrelevant little products..You see, I'm privy to information you silly little brain-washed grunts know nothing about..The fact is, you are a laughing stock to us docs..
     
  11. anonymous

    anonymous Guest

    "Us docs?"
    You sound like an idiot frat boy who probably can't even sell used cars. Probably still drunk from St Paddys day and came on here to bash one of the companies that wouldnt hire you.
     
  12. anonymous

    anonymous Guest

    You’re a dumbass troll. Nobody cares about your B.S.

    Yeah, dumb. You’re on a phishing expedition. Trying to get a rise out of someone, hoping they reveal themselves.

    Not gonna happen, “bro.”

    And how do you know I’m a “bro?”

    I could be “non-binary.”

    Go take a toke or two from your bong.

    Make it three, “bro.”
     
  13. anonymous

    anonymous Guest

    God, I love reading the responses of you hyper-sensitive little, entitled little douchebags with an incredibly over-inflated sense of self worth...You are irrelevant! You are a joke! You walk into an office, and believe you Bachelor of Liberal Arts dumbass is actually going to educate us docs on disease states of the eye?
    I spent years in medical school learning about anatomy, structure, and diseases pertaining to the eye!
    We all laugh at you behind your back! You are all the embodiment of extreme cases of the Dunning -Kruger effect!
     
  14. anonymous

    anonymous Guest

    I don't give a fuck what you call yourself..You're an irrelevant little bitch to me.
     
  15. anonymous

    anonymous Guest

    You’re an embarrassment to yourself.
     
  16. anonymous

    anonymous Guest

    You went to one shitty medical school if they spent years studying the eye. Was it one of those remedial med schools in the Carribean?

    Most of the time, sole focus on the eye occurs during 4 years of post graduate specialty training, followed by a 3 year surgical residency. I am sure that is what you meant, however. Many of the most accredited glaucoma specialists I deal with just say "med school" when they list their credentials

    Happy rep bashing, "bro"
     
  17. anonymous

    anonymous Guest

    Don’t waste your time engaging with this troll. They could the teenage son of a drug rep trash talking on here.

    Nothing the idiot makes sense and is meaningless.

    Ignore it.
     
  18. anonymous

    anonymous Guest

    seriously... a doctor on cafepharma? Yeah right. Idiot...
     
  19. anonymous

    anonymous Guest





    Aerie Pharmaceuticals, Inc. (AERI)
    NasdaqGM - NasdaqGM Real Time Price. Currency in USD

    46.82-2.43 (-4.93%)
    Profitability
    Profit Margin 0.00%
    Operating Margin (ttm) -867.38%
    Management Effectiveness
    Return on Assets (ttm) -45.57%
    Return on Equity (ttm) -127.99%
    Income Statement
    Revenue (ttm) 24.18M
    Revenue Per Share (ttm) 0.58
    Quarterly Revenue Growth (yoy) N/A
    Gross Profit (ttm) -3M
    EBITDA -207.3M
    Net Income Avi to Common (ttm) -232.57M
    Diluted EPS (ttm) -5.58
    Quarterly Earnings Growth (yoy) N/A
    Balance Sheet
    Total Cash (mrq) 202.82M
    Total Cash Per Share (mrq) 4.42
    Total Debt (mrq) N/A
    Total Debt/Equity (mrq) N/A
    Current Ratio (mrq) 4.34
    Book Value Per Share (mrq) 5.01
    Cash Flow Statement
    Operating Cash Flow (ttm) -152.58M
    Levered Free Cash Flow (ttm) -108.51M

    These numbers speak the honest, brutal truth...Your company is in a complete financial nose-dive into an early grave!..Enjoy this ride while you can, boys, girls, "non-binary"; because you will soon be out of jobs, and you will be selling insurance "1099 style" before you know it!
     
  20. anonymous

    anonymous Guest

    We are a startup company and it is expected that it will take several years to be profitable. We will be fine!!